What to Expect From Allergan Earnings

The company recently made a huge splash when it sold its generics portfolio to Teva for a whopping $40.5 billion.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women’s health, urology, cardiovascular and anti-infective therapeutic categories, and it operates the world’s third-largest global generics business. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

During this quarter, Allergan made moves to acquire Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH), which will greatly help in rounding out its portfolio of facial aesthetics.

Both companies announced that they have entered into a definitive agreement in which Allergan will acquire Kythera in a cash and equity transaction valued at $75 per Kythera share, or roughly $2.1 billion.

The transaction will be payable 80% in cash and 20% in new Allergan shares issued to Kythera stockholders. The acquisition is expected to be breakeven in 2016 and accretive thereafter.

Despite this acquisition, Allergan’s 2015 earnings per share (EPS) forecast provided on May 11 is unchanged. Thomson Reuters has a consensus estimate for 2015 earnings, which calls for $17.85 per share.

JPMorgan is acting as the financial advisor for Allergan, and Goldman Sachs is serving as the financial advisor for Kythera.

ALSO READ: 3 Potential Huge Biotech Takeover Targets

Through this acquisition, Allergan is looking to strengthen its leading global position in aesthetics and continues to position it for long-term growth. Kybella will offer patients new options beyond the traditional facial aesthetics while complementing Allergan’s market leading facial aesthetics portfolio.

Shares of Allergan were up 0.9% to $333.88 Wednesday afternoon. The stock has a consensus analyst price target of $371.41 and a 52-week trading range of $201.91 to $340.34.